There is limited published outcome data on the STARFlex device for transcatheter closure of atrial septal defects (ASD). To contribute to the long term outcomes of ASD device closure with the STARFlex device. Results of a prospective FDA approved clinical trial (1999-2001) from a single institution of the STARFlex device for simple ASD was reviewed. The inclusion criteria included age >or=2 years, isolated secundum ASD, evidence of right ventricular volume overload, and maximum stretched diameter <22 mm. a retrospective review of the original study data with most recent follow-up was performed. clinical success in the trial was defined as complete closure or residual leak>< 0.01). Of the 23 long term follow-up device patients, 23 (100%) achieved clinical success: 22 (96%) had complete closure at 1 year and latest echocardiographic follow-up and one case had a small <2 mm residual defect that has persisted. there have been no late complications with normalization of rv volumes in 92% and no deleterious ecg changes. device fractures occurred in 8 23 (35%) devices and were more common in the larger devices (p>< 0.05) but had no sequelae. None required any further intervention to treat the ASD and there were no infectious or thrombotic issues. In this cohort the STARFlex device for secundum ASD closure provided procedural success in 85% with failures due to surgical referral. All 23 patients with a STARFlex device with available long term follow-up had clinical success. Further long term data is required.
DOI 10.1002/ccd.21710
